Visible light mediated PVA-tyramine hydrogels for covalent incorporation and tailorable release of functional growth factors. (23rd July 2020)

• Record Type: Journal Article
• Authors: Atienza-Roca, Pau; Kieser, David C.; Cui, Xiaolin; Bathish, Boushra; Ramaswamy, Yogambha; Hooper, Gary J.; Clarkson, Andrew N.; Rnjak-Kovacina, Jelena; Martens, Penny J.; Wise, Lyn M.; Woodfield, Tim B. F.; Lim, Khoon S.
• Is Part Of: Biomaterials science. Volume 8:Number 18(2020)
• Page Start: 5005
• Page End: 5019
• Publication Date: 2020-07-23
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d0bm00603c
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : PVA-Tyr hydrogel facilitated covalent incorporation can control release of pristine growth factors while retaining their native bioactivity. Abstract : The translation of growth factors (GFs) into clinical applications is limited by their low stability in physiological environments. Controlled GF delivery through biomaterial vehicles provides protection from proteases, targeted delivery, and longer term release profiles. However, current methods used to incorporate GFs into biomaterials still present limitations. While direct adsorption and encapsulation result in burst release, covalent incorporation provides a tailorable release profile but generally requires more complicated processes and chemical modification of the GFs. Bioaffinity methods provide long-term release profiles but fail in their specificity, resulting in GF-dependent applicability and release profiles. In the present study, we introduce tyraminated poly-vinyl-alcohol (PVA-Tyr) as a GF-delivery vehicle that can covalently incorporate native GFs through a photo-initiated cross-linking process via formation of bi-phenol bonds. Mass loss and release studies revealed that protein-loaded PVA-Tyr hydrogels had highly tailorable degradation times from 7 to 92 days, during which the covalently incorporated proteins were released in a linear fashion. The incorporation of bovine serum albumin (BSA), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), or brain-derived growth factor (BDNF) resulted in similar incorporation efficiencies and release profiles, demonstrating the low specificity and versatility of the system. Furthermore, functional studies demonstrated that VEGF, bFGF and BDNF released from the PVA-Tyr hydrogels retained the ability to increase the metabolic activity, migration, and 3D vessel formation of endothelial cells and mesenchymal stem cells. Taken together, this demonstrates that PVA-Tyr shows high potential as a highly tailorable GF delivery tool for a range of different regenerative medicine applications.